Event calendar

ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

The presentations will be on demand via the ASRM Conference Portal

Wednesday, October 20, 2021, from 6:30-7:45 a.m. ET 

Details of the presentations are as follows:

Title: Efficacy and Safety of Linzagolix for the Treatment of Severe Adenomyosis: Final Results from a Pilot Study

  • Abstract: 11379
  • Poster Number: P-527
  • Presenter: Jacques Donnez
  • Session Date & Time: Poster presentation will be available through the ASRM conference portal, on Wednesday, October 20, 2021, from 6:30-7:45 a.m. ET 

Click here for article

Title:  Administration of Hormonal Add-Back Therapy (ABT) Counteracts the Uterine Volume Reducing Effects of Oral GnRH Antagonist Therapy

  • Abstract: 11462
  • Poster Number:  P-503
  • Presenter: Jacques Donnez
  • Session Date & Time: Poster presentation will be available through the ASRM conference portal, on Wednesday, October 20, 2021, from 6:30-7:45 a.m. ET 

Click here for Article

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue